September 22-23, 2022 Meeting of the Oncologic Drugs Advisory
- September 22-23, 2022 Meeting of the Oncologic Drugs Advisory Committee (ODAC) – Day 1 U.S. Food and Drug Administration
- U.S. FDA panel votes against Spectrum’s lung cancer drug Reuters
- FDA oncology nods will be challenging for Spectrum, Oncopeptides FiercePharma
- U.S. FDA staff raises concerns on Spectrum Pharma’s cancer drug Reuters
- View Full Coverage on Google News
Read More: September 22-23, 2022 Meeting of the Oncologic Drugs Advisory